Pasar al contenido principal

USO DE MODELOS CRISPR/CAS9 PARA ESTUDIAR EL IMPACTO DE MUTACIONES GENETICAS Y EPIGENETICAS CO-OCURRENTES EN LOS SINDROMES MIELODISPLASICOS

SAF2017-82171-R

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2017
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION PARA LA INVESTIGACION HOSPITAL UNIVERSITARIO LA FE

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Aberrant Alternative Splicing in U2af1/Tet2 Double Mutant Mice Contributes to Major Hematological Phenotypes

  • Martínez-Valiente, Cristina
  • Garcia-Ruiz, Cristian
  • Rosón, Beatriz
  • Liquori, Alessandro
  • González-Romero, Elisa
  • Fernández González, Raúl
  • Gómez-Redondo, Isabel
  • Cervera, José
  • Gutiérrez-Adán, Alfonso
  • Sanjuan-Pla, Alejandra
16 Pág. Departamento de Reproducción Animal​, Mutations in splicing factors are recurrent somatic alterations identified in myelodysplastic syndromes (MDS) and they frequently coincide with mutations in epigenetic factors. About 25% of patients present concurrent mutations in such pathways, suggesting a cooperative role in the pathogenesis of MDS. We focused on the splicing factor U2AF1 involved in the recognition of the 3' splice site during pre-mRNA splicing. Using a CRISPR/Cas9 system, we created heterozygous mice with a carboxy-terminal truncated U2af1 allele (U2af1mut/+), studied the U2af1mut/+ hematopoietic system, and did not observe any gross differences in both young (12-13 weeks) and old (23 months) U2af1mut/+ mice, except for a reduction in size of approximately 20%. However, hematopoietic stem/progenitor cells lacked reconstitution capacity in transplantation assays and displayed an aberrant RNA splicing by RNA sequencing. We also evaluated U2af1mut/+ in conjunction with Tet2-deficiency. Novel double mutant U2af1mut/+Tet2-/- mice showed increased monogranulocytic precursors. Hematopoietic stem/progenitor cells were also enhanced and presented functional and transcriptomic alterations. Nonetheless, U2af1mut/+Tet2-/- mice did not succumb to MDS disease over a 6-month observation period. Collectively, our data suggest that cooperation between mutant U2af1 and Tet2 loss is not sufficient for MDS initiation in mice., This work is supported by SAF2017-82171-R from the Spanish Ministry of Economy, Industry, and Competitiveness. C.M.-V. is funded by a predoctoral fellowship from Generalitat Valenciana (ACIF/2018/255). C.G.-R. is funded by AECC predoctoral fellowship. A.S.-P. is supported by the Ramón y Cajal Program (RYC2015-17534)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Concurrent Zrsr2 mutation and Tet2 loss promote myelodysplastic neoplasm in mice

  • Garcia-Ruiz, Cristian
  • Martínez-Valiente, Cristina
  • Cordón, Lourdes
  • Liquori, Alessandro
  • Fernández González, Raúl
  • Pericuesta Camacho, Eva
  • Sandoval, Juan
  • Cervera, José
  • Gutiérrez-Adán, Alfonso
  • Sanjuan-Pla, Alejandra
10 Pág., RNA splicing and epigenetic gene mutations are the most frequent genetic lesions found in patients with myelodysplastic neoplasm (MDS). About 25% of patients present concomitant mutations in such pathways, suggesting a cooperative role in MDS pathogenesis. Importantly, mutations in the splicing factor ZRSR2 frequently associate with alterations in the epigenetic regulator TET2. However, the impact of these concurrent mutations in hematopoiesis and MDS remains unclear. Using CRISPR/Cas9 genetically engineered mice, we demonstrate that Zrsr2m/mTet2-/- promote MDS with reduced penetrance. Animals presented peripheral blood cytopenia, splenomegaly, extramedullary hematopoiesis, and multi-lineage dysplasia, signs consistent with MDS. We identified a myelo-erythroid differentiation block accompanied by an expansion of LT-HSC and MPP2 progenitors. Transplanted animals presented a similar phenotype, thus indicating that alterations were cell-autonomous. Whole-transcriptome analysis in HSPC revealed key alterations in ribosome, inflammation, and migration/motility processes. Moreover, we found the MAPK pathway as the most affected target by mRNA aberrant splicing. Collectively, this study shows that concomitant Zrsr2 mutation and Tet2 loss are sufficient to initiate MDS in mice. Understanding this mechanistic interplay will be crucial for the identification of novel therapeutic targets in the spliceosome/epigenetic MDS subgroup., This investigation was supported by the grant SAF2017-82171-R to ASP from the Spanish Ministry of Economy, Industry, and Competitiveness. CGR is founded by JAP Valencia AECC predoctoral fellowships. CMV is sponsored by a predoctoral fellowship from Generalitat Valenciana (ACIF/2018/255). AL is funded by Generalitat Valenciana (APOSTD/2021/212). AGA was funded by grant RTI2018-093548-B-I00 from the Spanish Ministry of Science and Innovation. ASP is supported by the Ramón y Cajal Program (RYC2015-17534), Peer reviewed